Ind Swift completes USFDA audit for Clarithromycin facility

New Delhi, Feb 8 (UNI) Ind Swift Laboratories Ltd today said it has completed the United States Food and Drug Administration (USFDA) inspection for Clarithromycin Active Pharmaceutical Ingredient (API) manufacturing facility.

This would enable the company to roll out its API's in the North Amercian market.

Clarithromycin is used in the treatment of lower respiratory tract infections. The drug has a global market size of 1.3 million dollars.

The facility has already received the COS and TGA certifications.

The company's US-based wholly-owned subsidiary Ind-Swift Laboratories Inc has partnered with top US generic companies for generic pharmaceutical business.

''We are also working on alliances with biotechnology Companies in North America which will fuel our long term growth strategy,'' said Ind-Swift Laboratories Inc President Vikas Narendra.

The company has already filed 10 Drug Master Files (DMF's) and plans to file a significant number of DMF's with USFDA during next financial year, to enter the US market, the world's biggest generic drugs market.

Ind Swift Laboratories also said it is at an advanced stage of launching its drugs in the Japanese markets.

The company has a presence in over 45 countries and employs over 150 scientists.

UNI